| 词条 | Halometasone |
| 释义 |
| Verifiedfields = changed | Watchedfields = changed | verifiedrevid = changed | IUPAC_name = (6α,11β,16α)-2-Chloro-6,9-difluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione | image2 = Halometasone cream.jpg | width = 200 | image = Halometasone.png | width2 = 200 | tradename = Sicorten | Drugs.com = {{drugs.com|international|halometasone}} | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_UK = | legal_US = | legal_status = | routes_of_administration = Topical | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number_Ref = {{cascite|correct|??}} | CAS_number = 50629-82-8 | ChEMBL_Ref = {{ebicite|changed|EBI}} | ChEMBL = 1587228 | ATC_prefix = D07 | ATC_suffix = AC12 | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = | UNII_Ref = {{fdacite|correct|FDA}} | UNII = J69Z9UU41Z | PubChem = 9846332 | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID = 8022046 | smiles = O=C(CO)[C@]3(O)[C@]2(C[C@H](O)[C@]4(F)[C@@]/1(\\C(=C/C(=O)C(\\Cl)=C\\1)[C@@H](F)C[C@H]4[C@@H]2C[C@H]3C)C)C | StdInChI_Ref = {{stdinchicite|changed|chemspider}} | StdInChI = 1S/C22H27ClF2O5/c1-10-4-11-12-5-15(24)13-6-16(27)14(23)7-19(13,2)21(12,25)17(28)8-20(11,3)22(10,30)18(29)9-26/h6-7,10-12,15,17,26,28,30H,4-5,8-9H2,1-3H3/t10-,11+,12+,15+,17+,19+,20+,21+,22+/m1/s1 | StdInChIKey_Ref = {{stdinchicite|changed|chemspider}} | StdInChIKey = GGXMRPUKBWXVHE-MIHLVHIWSA-N | C=22 | H=27 | Cl=1 | F=2 | O=5 | molecular_weight = 444.896 g/mol | synonyms = (6S,8S,9R,10S,11S,13S,16R,17R)-2-chloro-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxy-acetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one }} Halometasone is a potent (Group III) synthetic tri-halogenated corticosteroid for topical application possessing pronounced anti-inflammatory, antiexudative, antiepidermoplastic, antiallergic, and antipruritic properties. It has been approved in many European countries including Spain, Germany, Switzerland, Austria, Netherlands, Belgium, and Portugal and other countries such as China, Hong Kong, Turkey, Israel, South Africa and India. It has been used to treat chronic psoriasis vulgaris[1] and non-infected acute eczematous dermatoses (eczema).[2] One study demonstrated that 0.05% halometasone cream was more effective than 0.05% betamethasone cream in treating dermatitis, though both were well-tolerated with no systemic adverse effects reported.[3] References1. ^{{cite journal |pmid=6339290 |year=1983 |last1=Galbiati |first1=G |last2=Bonfacini |first2=V |last3=Candiani |first3=F |title=Halometasone cream by day and halometasone ointment at night for the treatment of patients with chronic psoriasis vulgaris |volume=11 Suppl 1 |pages=31–3 |journal=The Journal of International Medical Research}} {{Glucocorticoids}}{{Glucocorticoidics}}2. ^{{cite journal |pmid=6339286 |year=1983 |last1=Yawalkar |first1=SJ |last2=MacArol |first2=V |last3=Montanari |first3=C |title=An overview of international clinical trials with halometasone cream |volume=11 Suppl 1 |pages=1–7 |journal=The Journal of International Medical Research}} 3. ^{{cite journal |pmid=6342285 |year=1983 |last1=Schuppli |first1=R |last2=Dressler |first2=H |last3=Yawalkar |first3=SJ |last4=Weirich |first4=EG |title=Comparative clinical trial of a new trihalogenated dermatocorticoid (halometasone) versus betamethasone dipropionate |volume=58 |issue=4 |pages=230–7 |journal=Zeitschrift für Hautkrankheiten}} 3 : Corticosteroids|Organochlorides|Organofluorides |
| 随便看 |
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。